Moving Forward Liquid Biopsy in Early Liver Cancer Detection
- 1 March 2023
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (3) , 532-534
Abstract
Summary: Early cancer detection is an attractive and promising application for liquid biopsy that might revolutionize cancer screenings. In this issue of Cancer Discovery, Foda and colleagues expand the potential utility of a machine learning fragmentome-based model, called DELFI, for detecting liver cancer in high-risk patients. See related article by Foda et al., p. 616 (5).Keywords
This publication has 10 references indexed in Scilit:
- Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detectionScience Translational Medicine, 2022
- Detecting Liver Cancer Using Cell-Free DNA FragmentomesCancer Discovery, 2022
- Urine DNA biomarkers for hepatocellular carcinoma screeningBritish Journal of Cancer, 2022
- Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation setAnnals of Oncology, 2021
- Detection and characterization of lung cancer using cell-free DNA fragmentomesNature Communications, 2021
- Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)Critical Reviews in Oncology/Hematology, 2020
- Liquid biopsy for early stage lung cancer moves ever closerNature Reviews Clinical Oncology, 2020
- Genome-wide cell-free DNA fragmentation in patients with cancerNature, 2019
- Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta‐analysis of a complex issueLiver International, 2017
- AASLD guidelines for the treatment of hepatocellular carcinomaHepatology, 2017